Drugs / ION283
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06609889 | Dec 2024 → Oct 2027 expected | Lafora disease | Berge Minassian | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION283 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06609889 ↗ |
| Modality | Antisense oligonucleotide | “Anti-sense Oligonucleotide therapy” NCT06609889 ↗ |
| Route | Intrathecal | “intrathecal (IT) injections” NCT06609889 ↗ |